Quick answers
- What is Acetazolamide used for?
- The FDA-approved label (Acetazolamide, Strides Pharma Science Limited, August 19, 2026) says: “For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Acetazolamide have a boxed warning?
- No. None of the 53 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Acetazolamide?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Acetazolamide been recalled?
- FDA enforcement reports list 2 recalls of products of this medicine; the newest started August 24, 2024 (Class III). A recall usually concerns specific lots, not every product.
- Who makes Acetazolamide?
- 38 companies list prescription products of Acetazolamide in the FDA NDC Directory, including Bryant Ranch Prepack, Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. and A-S Medication Solutions.
What Acetazolamide is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. …
— FDA label: Acetazolamide, Strides Pharma Science Limited, effective August 19, 2026. Read the full label on DailyMed →
The FDA has 53 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 53 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet · Capsule, extended release · Injection, powder, lyophilized, for solution · Capsule · Injection, powder, for solution |
|---|---|
| Route | Oral · Intravenous |
| Prescription products | 74 in the FDA NDC Directory |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| acetazolamide 125 mg tablet | Generic | $0.0964 per tablet |
| acetazolamide 250 mg tablet | Generic | $0.1317 per tablet |
| acetazolamide 500 mg capsule | Generic | $0.3017 per capsule |
| acetazolamide 500 mg capsule, extended release | Generic | $0.3017 per capsule |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bryant Ranch Prepack6 products
- Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.5 products
- A-S Medication Solutions4 products
- Zydus Lifesciences Limited3 products
- Chartwell RX, LLC3 products
- Zydus Pharmaceuticals USA Inc.3 products
- PD-Rx Pharmaceuticals, Inc.3 products
- Advagen Pharma Ltd2 products
- Marlex Pharmaceuticals, Inc.2 products
- Ajanta Pharma USA Inc.2 products
- AvKARE2 products
- Aurobindo Pharma Limited2 products
- Viona Pharmaceuticals Inc2 products
- Aarkish Pharmaceuticals NJ Inc.2 products
- Lifestar Pharma LLC2 products
- ANI Pharmaceuticals, Inc.2 products
- Strides Pharma Science Limited2 products
- NuCare Pharmaceuticals, Inc.2 products
- Eywa Pharma Inc2 products
- AvPAK2 products
- TruPharma, LLC2 products
- Hikma Pharmaceuticals USA Inc.2 products
- Mylan Institutional LLC2 products
- American Health Packaging1 product
- Ingenus Pharmaceuticals, LLC1 product
- Northwind Health Company, LLC1 product
- Remedyrepack Inc.1 product
- Proficient Rx LP1 product
- Micro Labs Limited1 product
- Major Pharmaceuticals1 product
- Alembic Pharmaceuticals Limited1 product
- NuCare Pharmaceuticlas, Inc.1 product
- Accord Healthcare Inc.1 product
- Westminster Pharmaceuticals, LLC1 product
- Alembic Pharmaceuticals Inc.1 product
- Sagent Pharmaceuticals1 product
- XGen Pharmaceuticals DJB, Inc.1 product
- Gland Pharma Limited1 product
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (23)
- ANDA040089Hikma · February 28, 1995
- ANDA040784Xgen Pharms · December 10, 2008
- ANDA040904Heritage Pharma · December 10, 2008
- ANDA090779Indicus Pharma · July 14, 2011
- ANDA200880Mylan Asi · May 9, 2012
- ANDA202693Avet Lifesciences · December 19, 2014
- ANDA203434Novast Labs · September 30, 2016
- ANDA205530Heritage Pharma · October 27, 2016
- ANDA209734Strides Pharma · November 20, 2017
- ANDA207659Accord Hlthcare · October 18, 2018
- ANDA205301Cadila · January 16, 2019
- ANDA210423Alembic · February 19, 2019
- ANDA210588Novitium Pharma · October 17, 2019
- ANDA211556Adaptis · October 18, 2019
- ANDA207401Micro Labs Ltd India · October 1, 2020
- ANDA214282Mankind Pharma · October 7, 2020
- ANDA211372Somerset Theraps LLC · February 22, 2021
- ANDA215101Rubicon Research · August 19, 2021
- ANDA211069Zydus Lifesciences · April 4, 2023
- ANDA217197Ne Rx Pharma · May 9, 2023
- ANDA211151Ajanta Pharma Ltd · September 11, 2023
- ANDA212089Aurobindo Pharma Ltd · May 30, 2025
- ANDA219775Gland · June 17, 2025
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
August 24, 2024 · Class III · Ongoing · D-0659-2024
Discoloration
AcetaZOLAMIDE Tablets, USP, 125 mg, 100 count bottled, Rx Only, Distributed by: Advagen Pharma Limited, Plainsboro, NJ, Manufactured by Rubicon Research Private Limited, Thane, India NDC 72888-047-01 — Rubicon Research Private Limited
-
March 15, 2021 · Class II · Terminated · D-0490-2021
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
AcetaZOLAMIDE Tablets, USP 125 mg 100 Tablets Rx only NDC 23155-287-01 Manufactured for: Heritage Pharmaceuticals Inc. Eatontown, NJ 07724 — Cardinal Health Inc.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 197303, 197304, 307702, 562524 |
|---|---|
| SPL set ID of the quoted label | 4813b9dd-5f58-44bb-ad64-cdb331828080 |
| FDA labels (SPL) | 53 |
| FDA applications | 23 ANDA |
| Active ingredients (FDA) | ACETAZOLAMIDE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Acetazolamide, Strides Pharma Science Limited, effective August 19, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →